Literature DB >> 30069522

Thirty-day complication and readmission rates associated with resection of metastatic spinal tumors: a single institutional experience.

Aladine A Elsamadicy1,2, Owoicho Adogwa3, David T Lubkin1, Amanda R Sergesketter1, Sohrab Vatsia1, Eric W Sankey1, Joseph Cheng4, Carlos A Bagley5, Isaac O Karikari1.   

Abstract

BACKGROUND: This study aims to assess 30-day complication and unplanned readmission rates associated with resection of metastatic spinal tumors.
METHODS: Medical records were reviewed for 135 adults who underwent elective resection of a spinal cord tumor. Patient demographics, comorbidities, and tumor characteristics were collected. Tumor pathology was analyzed and diagnosed by a pathologist. The primary outcomes were intra- and 30-day post-operative complication and readmission rates.
RESULTS: Of the 135 spinal tumor resections, 30 (22.2%) cases were metastatic. The most common tumor pathology was bone (13.3%) and the most common locations were thoracic (45.2%), and cervical (32.7%). Most patients had an open surgery (96.7%), with a mean laminectomy/laminoplasty level of 1.9±1.5 and mean operative time of 328.4±658.0 min. There was a 3.3% incidence rate of intraoperative durotomies, with no spinal cord or nerve root injuries. Post-operatively, 44.8% of patients were transferred to the intensive care unit (ICU). The most common post-operative complications were weakness (20.0%), new sensory deficits (16.7%), and hypotension (13.3%). The mean length of stay was 8.8±7.6 days, with the majority of patients discharged home (96.7%). The 30-day readmission rate was 9.7%, with the most common 30-day complications being uncontrolled pain (16.7%), sensory-motor deficits (13.3%), and fever (10.0%).
CONCLUSIONS: Our study suggests that weakness, sensory deficits, and uncontrolled pain are the most common complications after resection of spinal metastases, with a relatively high associated 30-day readmission rate. Further studies are necessary to corroborate our findings and identify strategies to reduce complication and readmission rates after resection of spinal metastases.

Entities:  

Keywords:  Spine; metastasis; postoperative complications; readmission; spine tumor

Year:  2018        PMID: 30069522      PMCID: PMC6046345          DOI: 10.21037/jss.2018.05.14

Source DB:  PubMed          Journal:  J Spine Surg        ISSN: 2414-4630


  35 in total

1.  Surgical strategy for spinal metastases.

Authors:  Henrik Bauer; Katsuro Tomita; Norio Kawahara; Mohamed E Abdel-Wanis; Hideki Murakami
Journal:  Spine (Phila Pa 1976)       Date:  2002-05-15       Impact factor: 3.468

Review 2.  Evidence-based review of the surgical management of vertebral column metastatic disease.

Authors:  Timothy C Ryken; Kurt M Eichholz; Peter C Gerszten; William C Welch; Ziya L Gokaslan; Daniel K Resnick
Journal:  Neurosurg Focus       Date:  2003-11-15       Impact factor: 4.047

3.  Surgical management of symptomatic spinal metastases. Postoperative outcome and quality of life.

Authors:  B Weigel; M Maghsudi; C Neumann; R Kretschmer; F J Müller; M Nerlich
Journal:  Spine (Phila Pa 1976)       Date:  1999-11-01       Impact factor: 3.468

Review 4.  Contemporary spinal oncology treatment paradigms and outcomes for metastatic tumors to the spine: A systematic review of breast, prostate, renal, and lung metastases.

Authors:  Amy Yao; Christopher A Sarkiss; Travis R Ladner; Arthur L Jenkins
Journal:  J Clin Neurosci       Date:  2017-04-24       Impact factor: 1.961

5.  Scoring system for the preoperative evaluation of metastatic spine tumor prognosis.

Authors:  Y Tokuhashi; H Matsuzaki; S Toriyama; H Kawano; S Ohsaka
Journal:  Spine (Phila Pa 1976)       Date:  1990-11       Impact factor: 3.468

6.  Complication, survival rates, and risk factors of surgery for metastatic disease of the spine.

Authors:  J J Wise; J S Fischgrund; H N Herkowitz; D Montgomery; L T Kurz
Journal:  Spine (Phila Pa 1976)       Date:  1999-09-15       Impact factor: 3.468

7.  Survival, complications and outcome in 282 patients operated for neurological deficit due to thoracic or lumbar spinal metastases.

Authors:  Karl-Ake Jansson; Henrik C F Bauer
Journal:  Eur Spine J       Date:  2005-03-03       Impact factor: 3.134

8.  Costs and readmission rates for the resection of primary and metastatic spinal tumors: a comparative analysis of 181 patients.

Authors:  Darryl Lau; Andrew K Chan; Alexander A Theologis; Dean Chou; Praveen V Mummaneni; Shane Burch; Sigurd Berven; Vedat Deviren; Christopher Ames
Journal:  J Neurosurg Spine       Date:  2016-04-29

Review 9.  Evaluation and treatment of spinal metastases: an overview.

Authors:  W B Jacobs; R G Perrin
Journal:  Neurosurg Focus       Date:  2001-12-15       Impact factor: 4.047

10.  Usefulness of Tokuhashi Score in Survival Prediction of Patients Operated for Vertebral Metastatic Disease.

Authors:  Marcelo Gruenberg; Maximiliano E Mereles; Gastón O Camino Willhuber; Marcelo Valacco; Matias G Petracchi; Carlos A Solá
Journal:  Global Spine J       Date:  2017-04-11
View more
  3 in total

Review 1.  [Intraoperative and late complications after spinal tumour resection and dorsoventral reconstruction].

Authors:  A Thomas; T Hollstein; S Zwingenberger; K-D Schaser; A C Disch
Journal:  Orthopade       Date:  2020-02       Impact factor: 1.087

2.  Characteristics and Predictors of Radiographic Local Failure in Patients With Spinal Metastases Treated With Palliative Conventional Radiation Therapy.

Authors:  Jie Jane Chen; Adam J Sullivan; Diana D Shi; Monica S Krishnan; Lauren M Hertan; Claudia S Roldan; Mai Anh Huynh; Alexander Spektor; M Mohsin Fareed; Tai Chung Lam; Tracy A Balboni
Journal:  Adv Radiat Oncol       Date:  2021-02-07

3.  Thirty- and 90-day Readmissions After Spinal Surgery for Spine Metastases: A National Trend Analysis of 4423 Patients.

Authors:  Aladine A Elsamadicy; Andrew B Koo; Wyatt B David; Cheryl K Zogg; Adam J Kundishora; Christopher S Hong; Gregory A Kuzmik; Ramana Gorrepati; Pedro O Coutinho; Luis Kolb; Maxwell Laurans; Khalid Abbed
Journal:  Spine (Phila Pa 1976)       Date:  2021-06-15       Impact factor: 3.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.